secwatch.observer — SEC 8-K summary
======================================

Issuer:     Repare Therapeutics Inc. (—)
CIK:        0001808158
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001193125-24-208814
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repare Therapeutics cuts workforce 25%, focuses on four clinical programs, extends cash runway to H2 2026
--------------------------------------------------------------------------------

- Board approved reprioritization; workforce reduction of ~25%, mainly in preclinical group, affected employees notified Aug 28, 2024.
- Expected one-time cash charges of $1.5M-$2.0M for termination benefits; substantially complete by Q3 2024.
- Annual cost savings of ~$15M extend cash runway into second half of 2026.
- Upcoming milestones: lunresertib+camonsertib data Q4 2024; potential registrational trial 2025; RP-3467 Phase 1 start Q4 2024.
- RP-1664 Phase 1 LIONS trial ongoing; plans to advance into pediatric neuroblastoma Phase 1/2 after safety data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808158/000119312524208814/0001193125-24-208814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808158/000119312524208814/d833928d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-208814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer